Detailed Narrative
H1 FY26 Financial Performance Overview
HVAX Technologies delivered a strong financial performance in H1 FY26, with total income reaching ₹62.79 crores, marking a 35% year-on-year growth. EBITDA for the period was ₹8.53 crores, an increase of 19% compared to ₹7.15 crores in H1 FY25. The company's net profit for H1 FY26 stood at ₹4.94 crores, reflecting a robust 29% year-on-year growth, demonstrating solid operational execution despite a dynamic environment.
Strategic Entry into Healthcare Infrastructure
A key development in H1 FY26 is HVAX's strategic move into the healthcare infrastructure segment through the proposed acquisition of Krew Instruments. This acquisition is expected to lay the foundation for multi-year growth by integrating project execution strength with specialized hospital and lab equipment, enabling turnkey healthcare solutions. Management emphasized that this move is not just about sector expansion but also about unlocking synergies, strengthening recurring revenue, and enhancing eligibility for larger domestic and international tenders.
Order Book and Pipeline Dynamics
The company maintains a healthy order book of ₹350 crores, complemented by an order pipeline of ₹650 crores, providing strong revenue visibility. Management indicated that the ₹350 crores order book is expected to be executed within one to two years. The conversion ratio for the pipeline is estimated at 20-25%. The order book composition is predominantly export-oriented, accounting for 75-80% of the total, and heavily concentrated in the pharmaceutical sector, representing 98-99%.
Margin Dynamics and Outlook
EBITDA margins in H1 FY26 experienced some compression, primarily attributed to a lower proportion of design-build projects and increased investment in sales and marketing activities. Design-built projects, which currently constitute 5-10% of the revenue mix, offer better margins compared to pure contracting projects. Management expects margins to improve and align with previous guidance for the full year, driven by a focus on higher-value engagements and project selectivity.
Diversification and Market Expansion
HVAX is actively pursuing diversification beyond its core pharmaceutical industry focus, exploring opportunities in hospitals, semiconductors, renewables, batteries, and chemicals. The acquisition of Krew Instruments is the first step in entering the hospital industry. The company's strategy involves cautious entry into new segments, with a strong emphasis on understanding margin profiles before scaling. Export markets are a key focus due to less competitive pressure and better margins compared to the domestic market.
Operational Focus and Growth Drivers
The company's growth strategy centers on disciplined execution, strengthening systems, and building capabilities to position HVAX as a trusted partner in mission-critical environments. Management reiterated a revenue growth guidance of around 35-40% for FY26 and the next couple of years. The primary challenge identified for future growth is human resource availability, for which the company is implementing initiatives like strategic partnerships with educational institutions and comprehensive training programs.